EP0215665B1
(fr)
*
|
1985-09-13 |
1991-11-21 |
Sankyo Company Limited |
Dérivés de l'hydroxy-ML-236B, leur production et utilisation
|
US4940727A
(en)
*
|
1986-06-23 |
1990-07-10 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
US5116870A
(en)
*
|
1986-06-23 |
1992-05-26 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
USRE36481E
(en)
*
|
1986-06-23 |
2000-01-04 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
US4833258A
(en)
*
|
1987-02-17 |
1989-05-23 |
Merck & Co., Inc. |
Intermediates useful in the preparation of HMG-COA reductase inhibitors
|
EP0306263B1
(fr)
*
|
1987-09-02 |
1992-03-18 |
Merck & Co. Inc. |
Inhibiteurs d'HMG-COA réductase
|
US4997848A
(en)
|
1987-10-27 |
1991-03-05 |
Sankyo Company, Limited |
Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
|
US4997755A
(en)
*
|
1988-04-15 |
1991-03-05 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
|
EP0337548A3
(fr)
*
|
1988-04-15 |
1991-08-14 |
Merck & Co. Inc. |
Inhibiteurs d'HMG-COA-réductase, produits par nocardia SP. (MA6455)(ATCC 53695)
|
US4963538A
(en)
*
|
1988-06-29 |
1990-10-16 |
Merck & Co., Inc. |
5-oxygenated HMG-CoA reductase inhibitors
|
US5041562A
(en)
*
|
1989-06-09 |
1991-08-20 |
Merck & Co., Inc. |
3-keto HMG-CoA reductase inhibitors
|
US4937259A
(en)
*
|
1989-06-09 |
1990-06-26 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US5010105A
(en)
*
|
1989-06-09 |
1991-04-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US5001241A
(en)
*
|
1989-06-09 |
1991-03-19 |
Merck & Co., Inc. |
3-KETO HMG-CoA reductase inhibitors
|
US4970231A
(en)
*
|
1989-06-09 |
1990-11-13 |
Merck & Co., Inc. |
4-substituted HMG-CoA reductase inhibitors
|
US4997849A
(en)
*
|
1989-06-23 |
1991-03-05 |
Merck & Co., Inc. |
Microbial transformation of simvastatin
|
US4965200A
(en)
*
|
1989-06-23 |
1990-10-23 |
Merck & Co., Inc. |
Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
|
US5112857A
(en)
*
|
1990-09-04 |
1992-05-12 |
Merck & Co., Inc. |
Hmg-coa reductase inhibitor metabolites
|
NZ250609A
(en)
*
|
1992-12-28 |
1995-07-26 |
Sankyo Co |
Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
|
US6043064A
(en)
*
|
1993-10-22 |
2000-03-28 |
Bristol-Myers Squibb Company |
Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
US5942423A
(en)
*
|
1995-06-07 |
1999-08-24 |
Massachusetts Institute Of Technology |
Conversion of compactin to pravastatin by actinomadura
|
SI9800144A
(sl)
|
1998-05-21 |
1999-12-31 |
LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. |
Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
|
SI20305A
(sl)
*
|
1999-08-06 |
2001-02-28 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Kristali natrijeve soli pravastatina
|
ATE360703T1
(de)
*
|
1999-01-20 |
2007-05-15 |
Kyowa Hakko Kogyo Kk |
Verfahren zur herstellung von hemmern der hmg-coa reduktase
|
CZ20012728A3
(cs)
*
|
1999-01-29 |
2002-02-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Způsob výroby inhibitorů HMG-CoA reduktasy
|
US6682913B1
(en)
|
1999-02-03 |
2004-01-27 |
Institute For Drug Research Ltd. |
Microbial process for preparing pravastatin
|
HUP9902352A1
(hu)
|
1999-07-12 |
2000-09-28 |
Gyógyszerkutató Intézet Kft. |
Eljárás pravasztatin mikrobiológiai előállítására
|
CZ20031166A3
(cs)
*
|
2000-10-05 |
2004-04-14 |
Biogal Gyogyszergyar Rt |
Sodná sůl pravastatinu, která v podstatě neobsahuje pravastatin lakton a epi-pravastatin a kompozice na její bázi
|
JP3236282B1
(ja)
*
|
2000-10-16 |
2001-12-10 |
三共株式会社 |
プラバスタチンを精製する方法
|
JP2003093045A
(ja)
*
|
2001-09-26 |
2003-04-02 |
Godo Shusei Co Ltd |
有用変換微生物
|
EP1496982A4
(fr)
*
|
2002-04-16 |
2006-07-19 |
Merck & Co Inc |
Formes solides de sels a activite tyrosine kinase
|
US20040198800A1
(en)
*
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
EP1578415B1
(fr)
|
2002-12-20 |
2008-09-10 |
Pfizer Products Inc. |
Formes posologiques comprenant un inhibiteur de cetp et un inhibiteur de hmg-coa reductase
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
KR100470078B1
(ko)
*
|
2003-06-12 |
2005-02-04 |
씨제이 주식회사 |
컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Streptomyces sp.)CJPV 975652 및 그를 이용한 프라바스타틴의 제조방법
|
CA2535359A1
(fr)
|
2003-08-21 |
2005-03-03 |
Merck Frosst Canada Ltd. |
Inhibiteurs de cathepsine et de cysteine protease
|
US20050101927A1
(en)
*
|
2003-09-11 |
2005-05-12 |
Kimberly-Clark Worldwide, Inc. |
Absorbent products comprising a moisturizing and lubricating composition
|
JP2007512359A
(ja)
|
2003-11-19 |
2007-05-17 |
メタバシス・セラピューティクス・インコーポレイテッド |
新規なリン含有甲状腺ホルモン様物質
|
TWI252253B
(en)
*
|
2004-01-09 |
2006-04-01 |
Chinese Petroleum Corp |
A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
|
KR100637762B1
(ko)
*
|
2004-07-30 |
2006-10-23 |
주식회사 지니스 |
저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
|
US20110217412A1
(en)
*
|
2004-07-30 |
2011-09-08 |
Jinis Biopharmaceuticals Co. |
Cholesterol lowering supplement and low cholesterol egg produced by using the same
|
TWI307360B
(en)
|
2004-12-03 |
2009-03-11 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Process for constructing strain having compactin hydroxylation ability
|
MX2007006878A
(es)
|
2004-12-09 |
2007-06-22 |
Merck & Co Inc |
Moduladores del receptor de estrogeno.
|
ES2510494T3
(es)
|
2005-03-02 |
2014-10-21 |
Merck Sharp & Dohme Corp. |
Composición para la inhibición de la catepsina K
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
BRPI0710540B1
(pt)
|
2006-04-19 |
2022-04-12 |
Novartis Ag |
Compostos de benzoxazol e benzotiazol substituídos por 6-o, e composição farmacêutica
|
WO2008039327A2
(fr)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
KR101591656B1
(ko)
|
2007-01-10 |
2016-02-19 |
엠에스디 이탈리아 에스.알.엘. |
폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸
|
CN101679266B
(zh)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
Pim激酶抑制剂及其应用方法
|
EP2152700B1
(fr)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Inhibiteurs du csf-1r, compositions et procédés d'utilisation
|
CA2690191C
(fr)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase
|
EP2222636B1
(fr)
|
2007-12-21 |
2013-04-10 |
Ligand Pharmaceuticals Inc. |
Modulateurs sélectifs du récepteur androgène (sarm) et leurs utilisations
|
US20110033904A1
(en)
*
|
2008-04-25 |
2011-02-10 |
Jun Seong Park |
Method for preparing orthodihydroxyisoflavones using a biotransformation system
|
WO2010093601A1
(fr)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
|
WO2010114780A1
(fr)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité akt
|
CN102638981B
(zh)
|
2009-10-14 |
2015-07-22 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
WO2011163330A1
(fr)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2613782B1
(fr)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
|
EP2615916B1
(fr)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
|
EP3766975A1
(fr)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2675440B1
(fr)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de cystéine protéases, les cathepsines
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2770987B1
(fr)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Nouveaux composés qui sont des inhibiteurs d'erk
|
WO2013165816A2
(fr)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Compositions de petit acide nucléique interférent (sina)
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
US9655899B2
(en)
|
2012-11-28 |
2017-05-23 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
TW201429969A
(zh)
|
2012-12-20 |
2014-08-01 |
Merck Sharp & Dohme |
作爲hdm2抑制劑之經取代咪唑吡啶
|
EP2951180B1
(fr)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
|
WO2015034925A1
(fr)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Polynucléotides circulaires
|
US9458181B2
(en)
|
2013-10-08 |
2016-10-04 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(fr)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de cystéine-protéases de type cathepsines
|
US10441567B2
(en)
|
2014-01-17 |
2019-10-15 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(fr)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de protéases à cystéine de type cathépsines
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2020033284A1
(fr)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
EP3833668A4
(fr)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
MX2022007535A
(es)
|
2019-12-17 |
2022-09-23 |
Merck Sharp & Dohme Llc |
Inhibidores de prmt5.
|